Leukemia & Lymphoma Society to launch 32nd Scenic Shore Bike Tour
The Leukemia & Lymphoma Society (LLS) is once again running its Scenic Shore Bike Tour to raise awareness and support for people with blood…
Patricia Inácio, PhD, science writer — 
Articles by Patricia Inácio
Survival in hard-to-treat myeloma extended with Elrexfio treatment
Pfizer’s Elrexfio (elranatamab) extends the lives of adults with relapsed or refractory multiple myeloma (RRMM) who received at least two prior lines of therapy and whose…
Bortezomib dosing once a week safer than twice a week: Study
Once-weekly induction therapy with bortezomib is as efficient as the standard two times a week dosing in people newly diagnosed with multiple myeloma, a…
Approval of a Darzalex Faspro therapy combo is sought in Europe
Johnson & Johnson has applied to the European Medicines Agency (EMA) for approval of its under-the-skin formulation of Darzalex (daratumumab), called…
Blenrep delays disease progression by nearly 3X versus Darzalex
GlaxoSmithKline (GSK)’s Blenrep (belantamab mafodotin) significantly reduced by more than half the risk of disease progression or death in people with relapsed or refractory…
Obesity, smoking, and poor sleep raise risk of myeloma precursor
Obesity, a history of heavy smoking, and limited sleep are risk factors for developing monoclonal gammopathy of undetermined significance (MGUS), a precursor condition to…
STAR-LLD combo showing potential for multiple myeloma in clinical trial
STAR-LLD, a continuous infusion of low-dose lenalidomide into the blood, shows the potential to be a better treatment choice than Revlimid, an oral formulation…
Blenrep works better than Darzalex as early therapy, trial data show
When added to a second-line combination therapy, Blenrep (belantamab mafodotin) — developed by GlaxoSmithKline (GSK) for relapsed or treatment-resistant …
Survival rates by race found similar with Abecma in myeloma study
Safety and response rates with Abecma (idecabtagene vicleucel) were seen to vary with race in people with relapsed or refractory multiple myeloma (RRMM), but…
Gene therapy targeting T-cells shows promise in myeloma animal models
A gene therapy designed by Kelonia Therapeutics to work as an off-the-shelf or readily available CAR T-cell therapy for multiple myeloma showed early…